“Our team is focused on developing new strategies to treat cancer that target key drivers of cancer that have previously not been druggable. With expertise in medicinal chemistry and tumor biology, we are developing first-in-class small molecule inhibitors for the treatment of therapy-resistant cancers. Our research is also identifying novel biomarkers to better leverage our targeted chemotherapies.”